Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus

Reumatol Clin. 2013 Nov-Dec;9(6):359-64. doi: 10.1016/j.reuma.2012.10.015. Epub 2013 Oct 5.

Abstract

Objective: To determine the incidence and prevalence of cancer in a cohort of patients with systemic lupus erythematosus (SLE) and identify associated risk factors.

Patients and methods: The study comprised a dynamic cohort of SLE patients (November 1989 to December 2006) at a tertiary referral centre. An adjusted external control from the hospital tumour registry was used.

Results: The study included 175 SLE patients (90% women), with a mean time at risk of 1370.5 patient-years. Fourteen women (8%) died, mainly from cardiovascular events. No patient died due to malignancy. We found 35 tumours in 28 patients, 25 of them after the diagnosis of SLE, of which 5 were malignant. The rate of benign tumours was 14.6/1000 patient-years (95% CI, 8.9-22.5) and of malignant tumours 3.6/1000 patient-years (95% CI, 1.5-8.8), with a crude incidence odds ratio for malignant tumours of 3.5 (95% CI, 1.5-7.9). However, this significance was lost after standardizing the rates. Concerning associated risk factors, differences were found in the mean erythrocyte sedimentation rate [HR 1.4 (1.1-1.7)], and the presence of thrombosis [HR 6.9 (1.49-41.2)], especially arterial thrombosis.

Conclusions: We found a crude incidence rate of cancer that was almost four times greater in our SLE patients as compared with the expected rate in the hospital area of western Malaga.

Keywords: Cancer; Cáncer; Incidence; Incidencia; Lupus eritematoso sistémico; Malignancy; Malignidad; Systemic lupus erytematosus.

MeSH terms

  • Adult
  • Female
  • Humans
  • Incidence
  • Lupus Erythematosus, Systemic / complications*
  • Male
  • Middle Aged
  • Neoplasms / epidemiology*
  • Neoplasms / etiology*
  • Prevalence
  • Prospective Studies
  • Risk Factors
  • Spain / epidemiology